Editas Looks To Upregulate Its Fortunes With In Vivo Editing

 
• By Andrew McConaghie
  
Editas
Editas's first in vivo gene therapy results underwhelmed last year, but the company could build on its leading position in 2022. • Source: Alamy

More from J.P. Morgan

More from Conferences